Chemigraphic expertise supports market introduction of Elekta Unity, a ground-breaking cancer treatment technology
The manufacturing and product development division of Electronics Manufacturing Services (EMS) provider Chemigraphic was part of a year-long process in supporting Elekta, a leading innovator in radiotherapy treatment and software, with bringing their newest cancer treatment system to market. Elekta Unity received CE mark in June and is the first of its kind, a high-field MRI-guided linear accelerator (linac) system that enables magnetic resonance radiation therapy (MR/RT), a new approach to cancer treatment.
Chemigraphic has been involved in the development of the product since 2014, conducting complex mechanical and bespoke PCB assemblies, and developing test and installation kits.
Chemigraphic’s focus on precision and early engagement, plus its ability to handle multiple assemblies from concept to production, has been a vital contributing factor in progressing the product’s route to market. Additional support throughout the testing and ongoing development stages, incorporating a number of engineering changes whilst maintaining consistency has further enabled the product to succeed in validation tests, resulting in the clinical introduction of Unity.
Barney Sheppard, Sales Operations Manager at Chemigraphic, comments: “Having been involved in this project since 2014, it is very gratifying to see the product launched onto the commercial and clinical market. It is humbling to be able to play a part in the development of a machine which will genuinely change and save lives, and we are very proud that our focus on seamless delivery and the highest quality assemblies has been a contributing factor in this project.”
The Elekta Unity MR-linac, which has been installed in MR/RT Consortium sites globally for research purposes, can now be used by and sold to hospitals throughout the UK and the EU.